Condition
Location

45 Migraine Trials

Power is an online platform that helps thousands of Migraine patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Image of trial facility.

Ubrogepant for Pediatric Migraine

Columbus, Ohio
This trial tests the safety and effectiveness of ubrogepant, a quick-relief migraine medication, in children aged 6-17 years. Ubrogepant works by blocking a protein that causes migraine pain. The study will involve regular check-ups over several months to ensure the treatment is safe and well-tolerated. Ubrogepant is an oral medication approved for the acute treatment of migraine in adults.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 3
Age:6 - 17
Sex:All
1200 Participants Needed
Image of trial facility.

Rimegepant for Pediatric Migraine

Columbus, Ohio
The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:6 - 17
Sex:All
2100 Participants Needed
Image of trial facility.

CBT + Amitriptyline for Childhood Migraine

Columbus, Ohio
This comparative effectiveness study will clarify current first-line preventive treatment approaches for use by neurologists, psychologists, and primary care providers in the context of real world care, and will demonstrate the feasibility of Cognitive Behavioral Therapy (CBT) via telehealth for youth with migraine. The focus is on applying evidence-based care and enhancing access to it. CBT via telehealth while taking a clinically-prescribed, pill-based prevention therapy (amitriptyline) will be compared to CBT via telehealth alone.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:10 - 17
Sex:All
400 Participants Needed
Image of trial facility.

Zanubrutinib + CAR T-Cell Therapy for Richter's Syndrome

Columbus, Ohio
This phase II trial tests how well zanubrutinib and lisocabtagene maraleucel (liso-cel) work together in treating patients with Richter's syndrome. Richter's syndrome occurs when chronic lymphocytic leukemia and/or small lymphocytic leukemia transforms into an aggressive lymphoma, which is a cancer of the lymph nodes. Zanubrutinib is a class of medication called a kinase inhibitor. These drugs work by preventing the action of abnormal proteins that tell cancer cells to multiply, which helps stop the spread of cancer. Liso-cel is a type of treatment known as chimeric antigen receptor (CAR) T cell therapy. CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Giving zanubrutinib and liso-cell together may kill more cancer cells in patients with Richter's syndrome.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
24 Participants Needed
Image of trial facility.

Rimegepant for Pediatric Migraine

Columbus, Ohio
This trial aims to test the safety of rimegepant, a medication for treating migraines. The study focuses on children and adolescents aged 6 to 17 years who experience moderate to severe migraines. Rimegepant works by blocking a protein that triggers migraine pain, helping to alleviate symptoms.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:6 - 17
Sex:All
600 Participants Needed
Image of trial facility.

Ubrogepant for Migraine

Columbus, Ohio
A migraine is a moderate to severe headache typically on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. Menstrual migraine (MM) is defined as migraine attacks that occur within the perimenstrual period (PMP) in at least 2 out of 3 menstrual cycles. The PMP is from 2 days before the onset of menstrual bleeding to 2 days after. This study will assess how safe and effective ubrogepant is in treating menstrual migraine. Adverse Events and change in disease activity will be assessed. Ubrogepant is an investigational drug being developed for short-term prevention of menstrual migraine. Participants will be randomly assigned to one of the 2 groups to receive either ubrogepant or placebo. Around 450 adult female participants with menstrual migraine will be enrolled in approximately 85 sites in the United States and Puerto Rico. Participants will receive oral ubrogepant tablets once daily for 7 consecutive days starting 3 days prior to estimated onset of menses per cycle for 3 PMPs during double-blind period (16 weeks). Eligible participants may continue to receive oral ubrogepant tablets once daily for 7 consecutive days per cycle starting 3 days prior to estimated onset of menses during open-label extension period (52 weeks). There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will collect data daily in electronic diaries and attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 45
Sex:Female
450 Participants Needed
Image of trial facility.

Ubrogepant for Pediatric Migraine

Columbus, Ohio
This trial will test if ubrogepant is safe and effective for young people with migraines. Ubrogepant is a medication taken by mouth to treat migraine headaches. It works by blocking a protein in the brain that causes migraine pain. The study focuses on children and adolescents who suffer from migraines.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:6 - 17
Sex:All
1059 Participants Needed
Image of trial facility.

Dysport for Chronic Migraine

New Albany, Ohio
This trial aims to test the safety and effectiveness of Dysport® in preventing chronic migraines. Dysport® is a drug that blocks pain-causing chemicals in the brain. Dysport® has shown good results in previous studies for preventing migraines. The study focuses on people who have frequent and severe migraines, with injections given over a period of more than a year.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
720 Participants Needed
Image of trial facility.

Dysport for Migraine Prevention

New Albany, Ohio
This trial aims to test the safety and effectiveness of Dysport® in preventing episodic migraines. Dysport® is injected into muscles to stop pain-causing chemicals in the brain. The study focuses on people with fewer than 15 headache days per month. Participants will undergo various assessments over a period of more than a year. Botulinum toxin type-A has demonstrated good efficacy in several studies of patients with migraine, although data from some trials have been conflicting.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
714 Participants Needed
Image of trial facility.

Intravenous Fluids for Childhood Migraine

Dayton, Ohio
The goal of this clinical trial is to compare intravenous (IV) fluids in pediatric patients with migraine. The main questions it aims to answer are: * Does a large amount of fluids (bolus) improve pain * Does a large amount of fluids (bolus) reduce admissions to the hospital for migraine Participants will be asked to report their pain and have vital signs checked every 30 minutes for two hours. Researchers will compare a large amount of fluids (bolus) to a small amount (half maintenance) to see if there is a difference in pain improvement.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:5 - 21
Sex:All
134 Participants Needed
Image of trial facility.

BHV-2100 for Migraine

Dayton, Ohio
This study is designed to identify at least one dose of BHV-2100 that is safe and effective in reducing headache pain and other symptoms in the treatment of migraine.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 64
Sex:All
575 Participants Needed
Image of trial facility.

Oral Atogepant Tablets for Migraine

West Chester, Ohio
This trial is testing a medication called atogepant to treat migraines in children and teenagers aged 6 to 17. The study aims to see if atogepant is safe and effective for this age group. Atogepant helps by blocking a protein that triggers migraines, potentially reducing their occurrence and intensity. Atogepant is a newly approved oral medication for the prevention of episodic migraine in adults.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:6 - 17
Sex:All
450 Participants Needed
Image of trial facility.

Rimegepant for Migraine Prevention in Children

Cincinnati, Ohio
This trial is testing rimegepant, a medication that prevents migraines, in children and teens who have occasional migraines. It works by blocking a protein that causes migraine pain. Rimegepant is taken orally and has shown effectiveness in treating migraines.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:6 - 17
Sex:All
640 Participants Needed
Image of trial facility.

Atogepant for Pediatric Migraine

West Chester, Ohio
A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. A number of treatments are available for adults with migraine but there are limited approved treatments available for participants less than 18 years of age. The main goal of the study is to evaluate the long-term safety and tolerability of atogepant in pediatric participants between the ages of 6 and 17 with migraine. Atogepant is a medicine currently approved to treat adults with migraine (0 to 14 migraine days per month) and is being studied in pediatric participants between the ages of 6 and 17 with a history of migraine. This is a Phase 3, open-label study of atogepant in participants with a history of migraine. Participants must have completed participation in another study of atogepant (lead-in study). Participants must have 4 to 14 migraine days and less than 15 headache days for episodic migraine, and \>= 15 headache days and \>= 8 migraine days for chronic migraine in the 4-week screening electronic diary (eDiary; similar to a smart phone). Around 650 participants will be enrolled in the study at approximately 100 sites worldwide. Atogepant is a tablet taken once a day by mouth. Participants between the ages of 12 and 17 will receive high dose atogepant for 52 Weeks. Participants between the ages of 6 and 11 will receive an atogepant dose determined in the lead-in study for 52 Weeks. There may be a bigger responsibility for participants in this study. Participants will attend regular visits during the study at a hospital or clinic. The effects of treatment will be checked by medical assessments, blood tests, checking for side effects, and completing questionnaires.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 3
Age:6 - 17
Sex:All
650 Participants Needed
Image of trial facility.

Lasmiditan for Pediatric Migraine

Cincinnati, Ohio
This trial is testing if lasmiditan is safe and effective for children aged 6 to 17 with migraines. The medication aims to block brain signals that cause migraine pain. The study will last several months and may include a few visits. Lasmiditan has been shown to be effective in treating acute migraine attacks in adults and is noted for its safety profile, particularly due to its lack of vasoconstrictive effects.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:6 - 17
Sex:All
1633 Participants Needed
Image of trial facility.

Lasmiditan for Pediatric Migraine

Cincinnati, Ohio
The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:6 - 17
Sex:All
1000 Participants Needed
Image of trial facility.

Atogepant for Migraine Prevention

Cincinnati, Ohio
This trial is testing a medication called Atogepant to see if it can safely and effectively prevent migraines in people who have them often. The medication works by blocking signals in the brain that cause migraines. Atogepant is a newly approved oral medication for the prevention of episodic migraine.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18 - 80
Sex:All
596 Participants Needed
Image of trial facility.

Fremanezumab for Preventing Chronic Migraine

Cincinnati, Ohio
The primary objective of the study is to evaluate the effectiveness of fremanezumab as compared to placebo for the preventive treatment of chronic migraine (CM). Secondary objectives are to further demonstrate the efficacy of Fremanezumab as compared to placebo for the preventive treatment of CM, to evaluate the safety and tolerability of Fremanezumab in the preventive treatment of CM and to evaluate the immunogenicity of Fremanezumab and the impact of antidrug antibodies (ADAs) on clinical outcomes in participants exposed to Fremanezumab The total duration of the study is planned to be 75 months.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:6 - 17
Sex:All
278 Participants Needed
Image of trial facility.

Galcanezumab for Pediatric Migraine

Cincinnati, Ohio
The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatment of episodic migraine. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:6 - 17
Sex:All
325 Participants Needed
Image of trial facility.

Eptinezumab for Pediatric Migraine

Cincinnati, Ohio
The main goal of this trial is to learn whether eptinezumab helps reduce the number of days with episodic migraine in pediatric participants.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:6 - 17
Sex:All
315 Participants Needed
Image of trial facility.

Eptinezumab for Chronic Migraine in Adolescents

Cincinnati, Ohio
This trial is testing if eptinezumab, given through an IV, can reduce migraine days in young people aged 12 to 17 who have chronic migraines. Eptinezumab works by blocking a protein that causes migraines. Participants will receive different amounts of the treatment to compare the effects. Eptinezumab has been shown to be effective and safe for preventing migraines in adults.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:12 - 17
Sex:All
285 Participants Needed
Image of trial facility.

Galcanezumab for Migraine

Cincinnati, Ohio
The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:12 - 17
Sex:All
300 Participants Needed
Image of trial facility.

Fremanezumab for Preventing Migraine in Children and Adolescents

Cincinnati, Ohio
This trial is testing an injectable medication called fremanezumab to prevent migraines in children and teenagers aged 6 to 17. The medication works by blocking signals in the brain that cause headaches. Fremanezumab has been investigated for the preventive treatment of migraine in adults.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:6 - 17
Sex:All
476 Participants Needed
Image of trial facility.

Qudexy XR for Pediatric Migraine Prevention

Cincinnati, Ohio
A Phase 4 study to evaluate Qudexy XR for the prevention of migraine in children 6 to 11 years of age.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:6 - 11
Sex:All
132 Participants Needed
Image of trial facility.

Online Intervention for Migraines

Cincinnati, Ohio
The objective of this trial is to test whether an online tailored intervention, Migraine Manager, is efficacious in improving headache outcomes compared to an attention control intervention in adolescents with migraines. We will conduct a randomized clinical trial to compare a sample of 80 youth (ages 11 to 17) with migraine receiving the online tailored adherence intervention to 80 youth in an attention control group. We will test whether adherence to healthy habit (hydration, regular meals, exercise, sleep) recommendations serves as a mechanism for improved headache outcomes. Clinically meaningful outcomes will be assessed by reliable, valid, and sensitive measures. The primary outcome (i.e., number of headache days) will be assessed via online daily diary pre- and post-intervention, with additional follow-up at 3, 6, 9, and 12 months. Secondary outcomes include health-related quality of life and migraine disability.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:11 - 17
Sex:All
160 Participants Needed
Image of trial facility.

Mind and Body Approaches for Migraine

Cincinnati, Ohio
The overarching objective of this protocol is to identify and understand the neural and pain processing mechanisms by which youth with migraine improve in response to preventive treatment. The study design of this mechanistic investigation includes functional magnetic resonance imaging (fMRI), daily headache diaries, assessment of conditioned pain modulation via quantitative sensory testing, and validated psychometric assessments before and after the delivery of one of five treatments over an 8 week period \[cognitive behavioral therapy (CBT), biofeedback-assisted relaxation training (BART) and cognitive reappraisal (CR) training, amitriptyline, and placebo\]. We are examining both distinct and common pathways that may help explain the response to various preventive treatments, as well as potential predictors of outcome.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:10 - 17
Sex:All
132 Participants Needed
Image of trial facility.

Mind-Body Balance for Pediatric Migraine

Cincinnati, Ohio
This study uses a factorial research design to evaluate a nurse delivered mind body intervention using different doses of 3 treatment components to determine the optimized treatment for headache day reduction.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:10 - 17
Sex:All
260 Participants Needed
Image of trial facility.

Atogepant + Botox for Chronic Migraine

Cincinnati, Ohio
This trial is testing a new daily pill called atogepant, used along with regular BOTOX treatments, to help prevent migraines. It targets adults who suffer from frequent and severe headaches. The pill works by blocking certain brain signals that trigger migraines. The study will monitor safety, side effects, and effectiveness over several months. Atogepant is a newly approved medication for the prevention of migraine.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18 - 75
Sex:All
75 Participants Needed
Image of trial facility.

Elismetrep for Migraine

Cincinnati, Ohio
This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the treatment of moderate or severe migraine.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 70
Sex:All
400 Participants Needed
Image of trial facility.

Brain Education and Wellness Program for Migraine

Cincinnati, Ohio
The goal of this randomized clinical trial is to evaluate two different non-drug, virtual treatment options designed to improve the lives of patients with migraine. Both interventions involve 8 weekly sessions and an online platform with additional content and learning. Participants can stay on all their medications during this study. Information from this study may help determine how to better treat migraine.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
286 Participants Needed
Page 1 of 2+

Frequently Asked Questions

How much do Migraine clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Migraine clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Migraine trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Migraine is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Migraine medical study ?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Migraine clinical trials ?

Most recently, we added MMA Embolization for Migraine, Rimegepant for Menstrual Migraine and Elismetrep for Migraine to the Power online platform.

Related Searches

By Condition

Headache Disorders Clinical Trials

Headache Clinical Trials

Obesity Clinical Trials

Pain Clinical Trials

Back Pain Clinical Trials

Cluster Headache Clinical Trials

By Location

Clinical Trials near New York, NY

Clinical Trials near Los Angeles, CA

Clinical Trials near Chicago, IL

Clinical Trials near Houston, TX

Clinical Trials near Miami, FL

Clinical Trials near San Francisco, CA

Other People Viewed

Pozelimab + Cemdisiran for Paroxysmal Nocturnal Hemoglobinuria (ACCESS-1 Trial)

Cultural-Based Intervention for Psychological Trauma in Native American Caregivers

Oral Atogepant Tablets for Migraine (ATO EM PEDS Trial)

Cancer Vaccine for BRCA Gene Mutation

Telehealth Intervention for Osteoporosis in Older Men (MisterFIt Trial)

CYAD-02 for Leukemia/Preleukemia (CYCLE-1 Trial)

Watchman for Atrial Fibrillation (WATCH-TMVR Trial)

mRNA-3927 for Propionic Acidemia

DWN12088 for Idiopathic Pulmonary Fibrosis

Probiotics for Long COVID Symptoms

Investigate the Efficacy and Safety of Farudodstat Compared With Its Placebo in Adult Alopecia Areata Participants

Marker-Directed Monitoring for Breast Cancer

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top